16 recruiting, 11 not yet recruiting, 9 completed, 6 unknown. 23 Phase 2, 19 Phase 1, 10 Phase 3, 4 Not applicable, 1 Early Phase 1.
Follow Pancreatic Cancer Metastatic: new trials by email Literature Review of Pancreatic Cancer Metastatic trials Research Report on Pancreatic Cancer Metastatic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC vilastobart (XTX101), Retifanlimab - Pancreatic Cancer Metastatic | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 40 | 2027-01-01 | 2026-08-14 |
| Intestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid Tumors With Liver Metastases Intestinal Low-Dose Radiotherapy (ILDR), PD-1/PD-L1 inhibitors, Combined Chemotherapy - Liver Metastases, Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Bing Xia | 120 | 2026-10-01 | 2026-10-15 |
| Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma daraxonrasib, gemcitabine, nab-paclitaxel - Pancreatic Cancer, Pancreatic Cancer Metastatic | Phase 3 | Recruiting | Revolution Medicines, Inc. | 400 | 2026-08-28 | 2026-10-16 |
| Study on the Construction and Application of a Large Model Corpus for Pancreatic Cancer Based on Real Clinical Cases Pancreatic Cancer, Pancreatic Cancer Metastatic | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 3000 | 2026-08-01 | 2026-07-21 | |
| MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer MT-601 dose 200 million cells, MT-601 dose 400 million cells, MT-601 dose 800 million cells - Pancreas Cancer, Pancreatic Cancer Metastatic | Phase 1 | Not yet recruiting | Marker Therapeutics, Inc. | 38 | 2026-07-16 | 2026-05-13 |
| Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Atebimetinib, GnP, mGnP - Pancreatic Cancer, Pancreatic Cancer Metastatic | Phase 3 | Recruiting | Immuneering Corporation | 510 | 2026-06-05 | 2026-10-23 |
| Predictive Value of Transcriptome-based OncoTreat/Oncotarget and Organoid Testing in Metastatic Pancreatic Cancer. Pancreas Neoplasms, Pancreatic Neoplasms | Not yet recruiting | Prof. Dr. med. Dres. h.c. Jan Schmidt, MME | 185 | 2026-06-01 | 2026-02-11 | |
| Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) Zoldonrasib, Placebo, Oxaliplatin - Pancreatic Cancer, Pancreatic Cancer Metastatic | Phase 3 | Recruiting | Revolution Medicines, Inc. | 670 | 2026-05-22 | 2026-10-13 |
| PhIbRandomGemcitabine(G)w/or w/Out Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC) Pitavastatin - Pancreatic Cancer, Pancreatic Cancer Metastatic | Phase 1 | Recruiting | University of California, Irvine | 18 | 2026-03-24 | 2026-05-04 |
| Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma daraxonrasib, gemcitabine, nab-paclitaxel - Pancreatic Cancer, Pancreatic Cancer Metastatic | Phase 3 | Recruiting | Revolution Medicines, Inc. | 900 | 2026-03-09 | 2026-10-02 |
| EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors EBNK-001 + IL-15 + Pembrolizumab - Cancer, Sarcoma | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 83 | 2026-02-01 | 2026-02-18 |
| Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic Cancer IBI363 + chemotherapy - Pancreatic Cancer Metastatic | Phase 1 / Phase 2 | Not yet recruiting | Ruijin Hospital | 48 | 2026-01-01 | 2026-01-15 |
| Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions Adebrelimab (PD-L1 inhibitor) - Pancreatic Cancer Metastatic | Phase 2 | Not yet recruiting | Sizhen Wang | 20 | 2025-11-30 | 2025-11-17 |
| Holistic Acupuncture for Patients With Chemotherapy Induced Nausea Holistic acupuncture and acupressure, Standard medical treatment - Breast Cancer, Prostate Cancer | Not applicable | Recruiting | Vejle Hospital | 90 | 2025-11-17 | 2026-05-28 |
| A Clinical Study Evaluating the Safety, Tolerability, Preliminary Efficacy and Immunogenicity of a Tumor Vaccine Injection Targeting Stressinducible Proteins MICA/B in Combination With the AG Regimen in Patients With Metastatic Pancreatic Cancer SapDM275 Tumor Vaccine Injection - Pancreatic Cancer Metastatic | Early Phase 1 | Not yet recruiting | The Third Xiangya Hospital of Central South University | 13 | 2025-11-01 | 2025-11-17 |
| Influence of Metastatic Sites on Survival Outcomes and Predictive Factors for Extended Survival in Metastatic Pancreatic Cancer a Retrospective Study Pancreatic Cancer Metastatic | Not yet recruiting | Assiut University | 60 | 2025-09-01 | 2025-07-25 | |
| A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer narmafotinib ascending doses, narmafotinib dose comparison - Pancreatic Cancer Metastatic | Phase 1 / Phase 2 | Active not recruiting | Amplia Therapeutics Limited | 67 | 2025-08-18 | 2026-05-05 |
| Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients TNG462, RMC-9805, RMC-6236 - PDAC, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Tango Therapeutics, Inc. | 183 | 2025-05-31 | 2026-10-23 |
| A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer Regorafenib combined with Toripalimab and Albumin paclitaxel - Pancreatic Cancer Metastatic | Phase 1 / Phase 2 | Recruiting | Junjie Hang | 23 | 2025-05-26 | 2026-05-18 |
| Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer Adebrelimab, AG - Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic | Phase 2 | Not yet recruiting | Jin Xu | 46 | 2025-04-15 | 2025-04-08 |
Showing 20 of 52. Sign in to see all of them.
Pancreatic Neoplasms (25) · Colorectal Neoplasms (3) · Lung Neoplasms (3) · Neoplasm Metastasis (3) · Adenocarcinoma (2) · Breast Neoplasms (2) · Disease (2) · Prostatic Neoplasms (2) · Carcinoma, Bronchogenic (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Colonic Neoplasms (1) · Esophageal Neoplasms (1) · Fanconi Anemia, Complementation Group D1 (1) · Glioblastoma (1)
Neoplasms (30) · Neoplasms by Site (30) · Digestive System Diseases (28) · Digestive System Neoplasms (28) · Endocrine Gland Neoplasms (25) · Endocrine System Diseases (25) · Pancreatic Diseases (25) · Pathological Conditions, Signs and Symptoms (6) · Lung Diseases (5) · Neoplasms by Histologic Type (5) · Neoplasms, Glandular and Epithelial (5) · Respiratory Tract Diseases (5) · Respiratory Tract Neoplasms (5) · Thoracic Neoplasms (5) · Carcinoma (4)
Gemcitabine (13) · 130-nm albumin-bound paclitaxel (7) · Oxaliplatin (5) · Leucovorin (4) · Albumin-Bound Paclitaxel (3) · Drug Therapy (3) · Fluorouracil (3) · Irinotecan (3) · Taxes (3) · Immune Checkpoint Inhibitors (2) · Radiotherapy (2) · folfirinox (2) · Acupressure (1) · Antineoplastic Combined Chemotherapy Protocols (1) · Celecoxib (1)
Revolution Medicines, Inc. (4) · Memorial Sloan Kettering Cancer Center (2) · Panbela Therapeutics, Inc. (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · Amplia Therapeutics Limited (1) · Arbeitsgemeinschaft medikamentoese Tumortherapie (1) · Assiut University (1) · Azienda Ospedaliera di Padova (1) · Bing Xia (1) · Boundless Bio, Inc. (1) · CSPC Ouyi Pharmaceutical Co., Ltd. (1) · Cornerstone Pharmaceuticals (1) · ElmediX (1) · Essen Biotech (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1)
United States (21) · China (11) · Germany (8) · Australia (5) · United Kingdom (5) · Belgium (4) · Italy (4) · Austria (3) · France (3) · South Korea (3) · Spain (3) · Canada (2) · Taiwan (2) · Brazil (1) · Denmark (1)
Nilofer Azad, MD (2) · Azeez Farooki, MD (1) · Bing Xia (1) · Eileen O'Reilly, MD (1) · Elizabeth Jaffee, MD (1) · Felix Keil, Prof.MD (1) · Giovanni Marchegiani, MD, PhD, Professor (1) · Harshabad Singh, MBBS MD (1) · Jan Schmidt, Prof. Dr. med. Dres. h.c., MME (1) · Jennifer J Knox, MD (1) · Jennifer Valerin, MD, PhD (1) · Jin Xu (1) · Marc Peeters, MD PhD (1) · Mark Middleton (1)
PMID 10819955, PMID 15273542, PMID 17051446, PMID 19801936, PMID 24457377, PMID 27956793, PMID 28353074, PMID 29325707, PMID 30430011, PMID 30834048, PMID 31512497, PMID 32558804, PMID 34665339, PMID 36374194, PMID 37678921, PMID 37741968, PMID 39088774, PMID 41526867, PMID 41642747, PMID 41766110, PMID 8580930
P50CA062924 (2), 2017 (1)